Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23401297 | 0.81 | LMNA (0.53) | LMNAPTGS2PTGS1ALDH1A1NPC1 | |
| SCHEMBL11653005 | 0.81 | LMNA (0.71) | LMNAPTGS2PTGS1ALDH1A1NPC1 | |
| SCHEMBL11323614 | 0.81 | LMNA (1.00) | LMNAPTGS2PTGS1ALDH1A1NPC1 | |
| SCHEMBL18593711 | 0.81 | RAB9A (0.62) | LMNAALDH1A1NPC1RAB9APOLB | |
| SCHEMBL19388861 | 0.80 | RAB9A (0.43) | LMNAPTGS1ALDH1A1NPC1RAB9A | |
| SCHEMBL1016466 | 0.79 | LMNA (0.67) | LMNAPTGS2PTGS1ALDH1A1NPC1 | |
| SCHEMBL13072707 | 0.78 | LMNA (0.61) | LMNAPTGS2PTGS1ALDH1A1NPC1 | |
| SCHEMBL20386628 | 0.78 | LMNA (0.43) | LMNAPTGS2PTGS1MEN1KMT2A | |
| SCHEMBL273437 | 0.78 | LMNA (0.65) | LMNAPTGS2PTGS1NPC1RAB9A | |
| SCHEMBL28400665 | 0.78 | LMNA (0.65) | LMNAPTGS2PTGS1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813932-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | RESPIVERT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| US-20190192515-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | RESPIVERT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-10301288-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-05-28 | — | — | US | disclosed |
| US-10238658-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180207158-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-9993478-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | Respivert, Ltd. (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20180086741-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9850233-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170312279-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | RESPIVERT LTD. (GB) | 2017-11-02 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| WO-2013004617-A1 | PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086741-A1 | KINASE INHIBITORS | SYK, BTK, SRC | LMNA 4049/4885PTGS2 704/4885PTGS1 726/4885 |
| US-10238658-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors | MAPK1, MAPK13, MAPK4 | LMNA 3176/4885PTGS2 84/4885PTGS1 56/4885 |
| US-10301288-B2 | Kinase inhibitors | SYK, BTK, SRC | LMNA 4049/4885PTGS2 704/4885PTGS1 726/4885 |
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | LMNA 1997/4885PTGS2 493/4885PTGS1 189/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | LMNA 2963/4885PTGS2 354/4885PTGS1 84/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | LMNA 2580/4885PTGS2 720/4885PTGS1 315/4885 |
| US-20170312279-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | LMNA 3360/4885PTGS2 121/4885PTGS1 65/4885 |
| US-10813932-B2 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | MAPK1, MAP3K1, MAP3K8 | LMNA 3360/4885PTGS2 121/4885PTGS1 65/4885 |
| US-20190192515-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | LMNA 3360/4885PTGS2 121/4885PTGS1 65/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | LMNA 2963/4885PTGS2 354/4885PTGS1 84/4885 |
| US-20180207158-A1 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | LMNA 3360/4885PTGS2 121/4885PTGS1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.